Skip to main content
Caplight Logo









Apnimed

Apnimed

Public
Cambridge, MassachusettsBiotechhttps://apnimed.com/

Apnimed is now publicly traded

The data on this page reflects Apnimed's private-market history up to the point it went public, including its funding rounds, valuation, and investors.

Went Public

Jul 31, 2026

Last Round

Debt

Mar 27, 2026

Total Funding Raised

$558.8M

Company Overview

Apnimed is a pharmaceutical company that develops novel oral therapies for the treatment of obstructive sleep apnea and other sleep-related breathing diseases.

Sector

Biotech

Verticals

HealthTech, Life Sciences, LOHAS & Wellness

AI Layer

Non-AI

Keywords

obstructive sleep apneaOSAsleep apnea pilloral pharmacologic therapyAD109sleep apnea treatmentclinical-stage biopharmanew drug applicationNDACPAP alternativeairway patencybiopharmaceutical developersleep medicinenon-invasive therapy

Apnimed Comparables

Compare Apnimed with similar companies based on industry and business-model similarity.

Apnimed comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Mosanna Therapeutics
80%
Shionogi & Co.
78%
Incannex Healthcare Inc.
78%

Apnimed Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
IPOJul 31, 2026
DebtMar 27, 2026
Convertible DebtSep 17, 2025
IPOJun 6, 2025
Series C ExtensionJan 3, 2023
Series C
May 4, 2022

Key People

Founding team and executive leadership

Mike Kelly

Chief Financial Officer

Executive Team

Luigi Taranto Montemurro

Chief Scientific Officer

Executive Team

Apnimed Investors

Notable investors and investment history

Apnimed investors
InvestorRounds
Evercore ISIIPO
Ameriprise FinancialSeries B
HealthCare Royalty PartnersDebt
Columbia Threadneedle InvestmentsSeries C, Series C Extension
Morningside VenturesSeries A, Series C, Series B
J. & W. Seligman & CompanySeries C, Series B
SectoralSeries C, Series C Extension

Recent news

Latest coverage and updates

  • has_revenueSep 22, 2026

    Apnimed had revenue of $12.1M on Sep 22nd '26.

  • is_developingSep 4, 2026

    Apnimed is developing AD109 on Sep 4th '26.

  • receives_financingJul 31, 2026

    Apnimed received financing of $192M in IPO on Jul 30th '26.

  • is_developingJul 31, 2026

    Apnimed will develop AD109 on Jul 1st '27.

  • is_developingJul 31, 2026

    Apnimed is planning to develop AD109.

Apnimed Filings

Explore SEC and related filing metadata, where available.

Apnimed filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range80
Year Founded2017
Last FundingMar 27, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?